{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"A prior dose level was defined as an RP2D if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).","groups":[{"description":"Participants received Cobimetinib (Suspension) formulation","id":"OG000","title":"Cobimetinib (Suspension) Population"}],"paramType":"NUMBER","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)","title":"Recommended Phase II Dose (RP2D) of Cobimetinib","type":"SECONDARY","unitOfMeasure":"mg/kg"}